Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Claritin syrup

This article was originally published in The Tan Sheet

Executive Summary

Claritin syrup: Schering-Plough's Rx loratadine syrup (10 mg per 10 ml) approved by FDA on Oct. 14 for "relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and for the treatment of chronic idiopathic urticaria in patients six years of age and older." Schering touts the product as "the first and only" Rx or OTC "nondrowsy antihistamine syrup for children." The pediatric remedy joins Claritin, Claritin-D 12-hour and the recently-approved Claritin-D 24-hour ("The Tan Sheet" Sept. 2, In Brief). The indication for Claritin 10 mg tablets also is expanded to children age six and over, Schering announces. Pfizer's Rx antihistamine Zyrtec (cetirizine), which is not considered non-sedating, was approved in a children's syrup formulation on Sept. 27. Both Claritin and Zyrtec are strong Rx-to-OTC switch candidates...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel